Combination of Genetic Signatures Identifies Ultra High Risk Multiple Myelomas
|
By LabMedica International staff writers Posted on 24 Mar 2020 |
|
Image: Histopathological image of multiple myeloma from a bone marrow aspirate (Photo courtesy of Wikimedia Commons)
Combining two panels of genetic biomarkers enabled cancer researchers to identify multiple myeloma patients at “ultra high risk” of progression of the disease and probable lack of response to lenalidomide, the primary drug used to treat it.
Investigators at the Institute of Cancer Research (London, United Kingdom) and their colleagues were seeking genetic signatures that would enable them to identify ultra high risk multiple myeloma patients. This effort involved analysis of the genomes of cancers obtained from 329 patients from across the United Kingdom who were participating in the phase III Cancer Research UK Myeloma XI trial, which evaluated the effectiveness of a range of targeted drugs, including lenalidomide.
Results revealed that 81 of the patients had cancers with the “SKY92” signature, a pattern of gene activity involving 92 genes linked to high-risk status. Patients with cancers that carried the SKY92 high risk gene expression signature had an up to three-fold increased risk of their cancer recurring early. Those with heavily genetically mutated (double-hit) cancers had a two-fold increased risk of death.
About 10% of the total patient group had cancers with both the SKY92 signature and double-hit genetic features. Patients in this group were at ultra high risk of early, aggressive disease relapse, with all cancers in this group progressing within four years. Furthermore, those with ultra high risk disease had an 11-fold increased risk of death compared with other patients. The patients in this ultra high risk group were found to not respond to lenalidomide as ongoing or maintenance therapy.
Senior author Dr. Martin Kaiser, teamleader in myeloma molecular therapy at The Institute of Cancer Research, said, “Our study shows that people whose tumors have an “ultra high risk” combination of genetic features have particularly aggressive disease which does not respond sufficiently to standard treatment to keep their cancer at bay. Testing for high-risk genetic features could help target myeloma treatment, focusing on the specific needs of each patient. Not all patients with myeloma are the same, and we know that by better understanding their cancer's genetic and molecular features, we can tailor their treatment much more effectively.”
The multiple myeloma study was published in the March 11, 2020, online edition of the journal Leukemia.
Related Links:
Institute of Cancer Research
Investigators at the Institute of Cancer Research (London, United Kingdom) and their colleagues were seeking genetic signatures that would enable them to identify ultra high risk multiple myeloma patients. This effort involved analysis of the genomes of cancers obtained from 329 patients from across the United Kingdom who were participating in the phase III Cancer Research UK Myeloma XI trial, which evaluated the effectiveness of a range of targeted drugs, including lenalidomide.
Results revealed that 81 of the patients had cancers with the “SKY92” signature, a pattern of gene activity involving 92 genes linked to high-risk status. Patients with cancers that carried the SKY92 high risk gene expression signature had an up to three-fold increased risk of their cancer recurring early. Those with heavily genetically mutated (double-hit) cancers had a two-fold increased risk of death.
About 10% of the total patient group had cancers with both the SKY92 signature and double-hit genetic features. Patients in this group were at ultra high risk of early, aggressive disease relapse, with all cancers in this group progressing within four years. Furthermore, those with ultra high risk disease had an 11-fold increased risk of death compared with other patients. The patients in this ultra high risk group were found to not respond to lenalidomide as ongoing or maintenance therapy.
Senior author Dr. Martin Kaiser, teamleader in myeloma molecular therapy at The Institute of Cancer Research, said, “Our study shows that people whose tumors have an “ultra high risk” combination of genetic features have particularly aggressive disease which does not respond sufficiently to standard treatment to keep their cancer at bay. Testing for high-risk genetic features could help target myeloma treatment, focusing on the specific needs of each patient. Not all patients with myeloma are the same, and we know that by better understanding their cancer's genetic and molecular features, we can tailor their treatment much more effectively.”
The multiple myeloma study was published in the March 11, 2020, online edition of the journal Leukemia.
Related Links:
Institute of Cancer Research
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Human Estradiol Assay
Human Estradiol CLIA Kit
Laboratory Software
ArtelWare
Latest Molecular Diagnostics News
- Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
- Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
- Genetic Marker to Help Children with T-Cell Leukemia Avoid Unnecessary Chemotherapy
- Four-Gene Blood Test Rules Out Bacterial Lung Infection
- New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis
- New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
- World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
- Blood Test to Help Low-Risk Gastric Cancer Patients Avoid Unnecessary Surgery
- First-Of-Its-Kind Automated System Speeds Myeloma Diagnosis
- Blood Protein Profiles Predict Mortality Risk for Earlier Medical Intervention
- First Of Its Kind Blood Test Detects Gastric Cancer in Asymptomatic Patients
- Portable Molecular Test Detects STIs at POC in 15 Minutes
- Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device
- POC Bordetella Test Delivers PCR-Accurate Results in 15 Minutes
- Pinprick Blood Test Could Detect Disease 10 Years Before Symptoms Appear
- Refined C-Reactive Protein Cutoffs Help Assess Sepsis Risk in Preterm Babies
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Immunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read more
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
